

## Newsletter of MARCH 2024 content.

We had a very intense period!

- 1. Event outcome of the past month (February March)
- 2. Event outcome of the forthcoming month (April and May)
- 3. OHD Action project related meetings
  - Highlights Natural products meeting 27 February 2024
  - Highlights from the OHD1\_Target database project (Project OHD1 -Target Database 4-3-2024)
  - Highlights from the OHD2\_Compounds database project (Project OHD2 -Compounds Database 11-3-2024
  - Grants application 1<sup>st</sup> meeting (29 February 2024)
  - Paper SOP animal models -20-11.30 meeting
- 4. NEW! In presence meeting: ATTENTION NEEDED!
  - Porto meeting contact 15-17 May (contact loana Tavares and Ana Tomas)
  - Rome meeting (June 18-20) for YRI (contact Elisa Uliassi)
  - Oxford annual meeting 3-5 July (for now contact MP Costi)
- 5. NEW! Training schools Alert about Naples school on Natural products and antiparasitic drugs
- 6. STSM 4th call opening on February 1st deadline 15 March 2024. This is the second and final STSM call. Deadline postponed to 31<sup>st</sup> of March.
- 7. Conference grants application is over. Just 1 application. Remaining grant shifted to events in presence.
- 8. Publication in the ACS Infectious diseases Issue deadline for submission 1<sup>st</sup> May.
- 9. NEW! grants application
- 10. Surveys status 2 SURVEYS closed. Monitoring of the open ones.
- 11. SciCom communication

• Event outcome of the past month (February – March)

## 1. List of the event in February

HG3 Training school meeting 13/02/2024 11:00-13:00 (VIRTUAL):

6thMC meeting 20th February 2024 14:30-17:30 (VIRTUAL)

ADVANCING RESEARCH ON HELICOBACTER PYLORI INFECTION IN CAMEROON: PREVALENCE, PROGRESS, AND CHALLENGES 27 February 2024 Corinne – Seminar from the University of Modena and Reggio Emilia

## 2. List of events in March and connection to the OHD-projects!

Color code:

Blue: official meeting of the chair and the network (Core group meetings, Mangement Committee Meetings, General Assembly)

Yellow: Workshops organized by the WG leaders and their teams in presence or in remote Pink: Internal working group meetings

### Core Group meeting 25th March 2024 14:30-16:00 (VIRTUAL)

WG2 HG7 Workshop "Green chemistry approaches and innovative drug delivery systems towards reducing environmental impact in antiparasitic drug discovery" 15th March 2024 14:00-17:00pm (VIRTUAL).

WG6 Workshop "Minimising the risk of rapid-onset (cross) resistance in PVBD drug development [strategies to assess the risk of rapid resistance developing]" 18th March 2024 14:00-16:00 pm CET (VIRTUAL)

Project OHD1 - Target Database 4-3-2024

### Project OHD2 -Compounds Database 11-3-2024.

### Highlights!

This project has the double aims to develop a database and a paper.

We expect that the paper can be a research paper. The title **"Antiparasitic drug discovery and emerging scaffold with predictive low environmental impact**", the paper is organized as reported below:

Paper SOP animal models -20-11.30 meeting

#### WG1 internal meeting 27th March 2024 15:00-16:00 pm CET (VIRTUAL)

List of EVENTS that will be held in April 2024

WG2 meeting 5th April 2024 15:00-16:00 pm CET (VIRTUAL)

HG2 STSM Grants awarding group meeting 8th April 3-4pm 2024 11:00-13:00 (VIRTUAL)

WG1 Workshop " Structural and functional aspects of targets involved in vector borne diseases" 17th April 2024 (VIRTUAL)

WG5 meeting 19th April 2024 15:00-17:00 pm CET (VIRTUAL)

WG6 meeting 22nd April 2024 14:30-15:30 pm CET (VIRTUAL)

List of EVENTS that will be held in May 2024

WG3,WG4, WG6, HG4, HG5 Thematic Workshop "Animal friendly and environmentally relevant systems to replace or refine animal tests during drug developmental processes for VBD" I3S, Porto, Portugal, 14-15 May 2024

WG3 meeting 24th May 2024 13:00-15:00 pm CET (VIRTUAL)

WG1 meeting 29th May 2024 15:00-16:00 pm CET (VIRTUAL)

#### 3. OHD Action project related meetings

- Highlights Natural products meeting 27 February 2024
- Highlights from the OHD1\_Target database project (Project OHD1 Target Database 4-3-2024)
- Highlights from the OHD2\_Compounds database project (Project OHD2 -Compounds Database 11-3-2024
- Grants application 1<sup>st</sup> meeting (29 February 2024)
- Paper SOP animal models -20-11.30 meeting

### Highlights Natural products meeting 27 February 2024

ADVANCING RESEARCH ON HELICOBACTER PYLORI INFECTION IN CAMEROON: PREVALENCE, PROGRESS, AND CHALLENGES 27 February 2024 Corinne – Seminar from the University of Modena and Reggio Emilia

#### Highlight from Corinne's seminar in Modena

Natural extracts availability discussion followed the seminar presentation.

Prof. Njayou Frederic Nico and Dr. Tchamgoue Deutou

The presentation done by Dr Ngnameko was very informative regarding *H. pylori* infection in Cameroon, treatment approaches and challenges. From the discussion followed, many medicinal plants are used by population against the disease and exploration of these species is a promising way to solve the problem. This fight can be strengthened through a collaborative work between Cameroonian research team and Italian partners or COST OHD partners to overcome the lack of equipment for further chemical and biological studies. Cameroonian research team hopes a lot from this collaboration.

Taking the opportunity of Corinne presence at UNIMORE, we planned to involve Corinne's professors in a collaboration based on the evaluation of natural products extracts from Cameroon plant. The contacts are:

- Prof. Njayou Frederic Nico, Laboratory of Pharmacology and Toxicology, Department of Biochemistry, Faculty of Sciences, University of Yaounde 1.
- Dr. Tchamgoue Deutou Armelle, Laboratory of Pharmacology and Drug Discovery, Centre for Research on Medicinal Plants and Traditional Medicine, Institute of Medical Research and Medicinal Plants Studies (IMPM).

Dr. Corinne Ngnameko is the scientist of reference to support this collaboration. **OUTCOME: new natural compounds extract source and collaboration available** 

### Highlights from the OHD1\_Target database project (Project OHD1 - Target Database 4-3-2024) Cecilia Pozzi and Ulrike Wittig and Marco Mazzorana

The OHD1 Target database responds to the Goal for WG1 - YEAR 2: Define the biological target criteria and start collection of target data [WG1] ongoing and to the following deliverable: D7 Report on target selected and structural biology. M36 (WG1) This is also connected to the events of the 17 of April entitled "Structural and functional aspects of targets involved in vector borne diseases. Lun 4 mar, 15:38 Dear All, thanks for participating in today's meeting and for collaborating in the project. Today we have presented the project, the generation of a template for collecting information on the targets available within the CA21111 and we have started to work on a world doc as initial draft to collect info for the database. We have defined the main sections and some parameters within them. As we discussed today, I have shared a folder for the BioTarget Database (https://drive.google.com/drive/u/0/folders/1WWOmtDV9JTO2d3V9pAcoKypvOphYervC), you should have received a separate email on it. Inside the folder you can find the file "BioTarget DB template CA21111.docx" (https://docs.google.com/document/d/1DetGhZqlzJAO5CfbLR11T0K28\_T1YcmL/edit) Please fill free to add new sections and to add parameters in each section already present in the file. You can also modify the parameters/sections (or suggest possible alternative names). Please let me know if you have any questions or problems with the shared documents. We will meet up in 10-15 days to discuss the state of the art. I will send you a Doodle by Friday to agree on the date/time for the next meeting. Thanks. best regards, Cecilia

OUTCOME: Target collection for VBPD, new potential targets to be identified, new profile expected for these targets including the predictive distribution among organisms present in the environment.

> Highlights from the OHD2\_Compounds database project (Project OHD2 -

### Project OHD2 -Compounds Database 11-3-2024. Highlights!

This project has the double aims to develop a database and a paper.

We expect that the paper can be a research paper. The title "Antiparasitic drug discovery and emerging scaffold with predictive low environmental impact", the paper is organized as reported below:

Section¤	Scientist(s) in Charge¤					
1. Database discussion	U. Wittig ( <u>ulrike.wittig@h-its.org</u> )¤					
2. Collection of recent drugs	۲		Medicinal chemists involved			
2.1 Leishmania¤	C.· Borsari°· ( <u>chiara.borsari@unimi.it</u> °)· E.· Uliassi·( <u>elisa.uliassi3@unibo.it</u> )¤		in the field of T.brucei,			
2.2 HAT¤	M. Tonelli ( <u>michele.tonelli@unige.it</u> )¤		malaria, natural compounds are invited to join the project			
2.3 Chagas¤	T. Calogeropoulou ( <u>tcalog@eie.gr</u> )¤					
2.4 Babesia¤	S.∙Gemma (gemma@unisi.it)¤					
2.5 Schistosomiasis¤	S. Gemma (gemma@unisi.it)¤	1.Contact: Theodora Calogeropoulou				
2.6 Malaria¤	S. Blandin¤	tcalog@eie.gr				
Coordination of natural compounds collection	T.·Schmidt¤	2.Gemma Sandra - gemma@unisi.it				
3. Scaffold retrieval	S. Gul (sheraz.gul@itmp.fraunhofer.de)¤					
4. Ecotox evaluation of the scaffolds	M. Bertram/E. Thore/S. Gul¤					

**This activity is connected with the YEAR 2 goal "**Upload of compound data and setup of database structure **[WG1 + WG2]"** and the In silico assessment of ecotoxicology properties of hits and leads **[WG2 + WG3+**HG6+HG7] because an ecotoxicology evaluation will be performed on the scaffold. And to the deliverables: D18\_Report about compounds collections. M48 (WG1)

OUTCOME: the research paper is organized and the collection of the compounds in the latest 5 years started. The criteria to select the compounds is based on scaffold collections, the criteria are related to the target product profile for HIT compounds for the different diseases. These scaffolds will be examined for a predictive ecotoxicology profile.

### Grants application 1<sup>st</sup> meeting (29 February 2024)

The meeting was participated by 63 participants interested in contributing to the grant applications.

Unfortunately, the calls are very close and there is no sufficient time to plan the Grant. The topic is on virus borne diseases and it is peripheral with respect to the OHD topic.

Theodora Calogeropoulou and Maria Laura Bolognesi proposed to develop a MSCA application within the OHD project.

OUTCOME: there will be initiatives on the development of MSCA applications.

#### Paper SOP animal models -20-3-11.30am meeting

This activity relates to the WG3 goal of YEAR 1 entitled **"SOP coordination for animal experiment standardization [WG3]** and Roadmap toward a position paper on animal experiment standardization **[WG3]**.

Moreover, it is linked to the deliverable: D14\_Report on SOP coordination on standardization of animal experiments. M42 (WG3).

**OUTCOME:** SOP standardization and stakeholder communication

### 4. NEW! In presence meeting: ATTENTION NEEDED!

EVENTS in progress

Upcoming Agenda: Action's Works Unfold. Our current lineup of events, each designed to contribute significantly to our strategic goals and collaborative efforts.

a. 1st Training School "Natural products in parasitic diseases". 18-20 June 2024 - 3days school, University of Naples, Naples (Italy) **ONGOING** 

b. WG3, WG4, WG6, HG4, HG5 Thematic Workshop "Animal friendly and environmentally relevant systems to replace or refine animal tests during drug developmental processes for VBD" 13S, Porto, Portugal, 14-15 May 2024 visit the Website: https://www.i3s.up.pt/event.php?v=312

c. Workshop "Medicinal chemistry process within the OneHealth perspective for YRI " 18 th June 2024 Rome (Italy) ONGOING

*d.* ANNUAL OHD CONFERENCE "Structural and functional drug discovery for vector-borne diseases". Oxford (UK) 3-5 July 2024 ONGOING

e. WG1 WG2 HG7 Thematic Workshop: "Novel leads and drugs for vector borne diseases: Targets and off targets (toxicity and ecotoxicity) and mechanism of action" September 19-20 2024, National Hellenic Research Foundation, Athens, Greece

*f.* 2nd Training School "Cell culture as in vitro models for newly developed drugs against vector borne parasitic diseases within the One Health perspective". 25- 26-27 September 2024 -3 days school. University of Warsaw, Poland

## 5. NEW! Training schools – Alert about Naples school on Natural products and antiparasitic drugs

Title: Natural products in antiparasitic drug discovery: experimental and computational approaches

Date: 18 June – 20 June 2024

Department of Pharmacy- University of Naples "Federico", Naples, Italy

**Organizers:** Caterina Fattorusso Imperatore Concetta, Marialuisa Menna, Orazio Taglialatela Scafati **Description:** 

Natural products and their (semi)synthetic derivatives have played a significant role in the discovery of antiparasitic drugs. Plants and marine organisms have been identified to be sources for the isolation and identification of natural products with very high degree of chemical diversity, making them a generous source of hit structures for drug discovery. The identification of new hits as well as the subsequent hit to lead optimization process rely on both computational and experimental approaches. The focus of this training school will be to explore the principles underlying i) methods for isolation and structural characterization of antiparasitic metabolites from plants and

marine organisms, ii) in silico methods for hit identification and optimization, and iii) green synthetic approaches for structural optimization. A combination of lectures and practical work sessions will provide an engaging experience and help the participants to prepare for playing a leading role in the future research efforts in this field.

# 6.STSM 4th call opening on February 1st deadline 15 March 2024. This is the second and final STSM call. Postponed to 31<sup>st</sup> of March



## 7. Conference grants application is over.2 applications. Remaining grant shifted to events in presence.

## 8. Publication in the ACS Infectious diseases Issue deadline for submission 1<sup>st</sup> May.

NEW! publication accepted in the ACS Issue! And other publications submitted with the COST acknowledgment: information received.

Some papers already accepted. From the Editor "16 manuscripts have been accepted and 14 are under review. So, potentially, 30!"

### 9. NEW! grants application:

- > List of currently identified open applications of potential interest.
- This is not intended as an exhaustive list of open calls, but a selection of the chair. Those who are interested, can alert about other calls.
- We are all encouraged to participate/lead projects involving our network participants, (not exclusively OHD participants)
- If you apply (inside or outside the OHD Action) please inform the Chair, it is important to list the activities stemming from and thanks to the OneHealthdrugs action

## 1. HORIZON EUROPE projects - OHD contact: Anabela Cordeiro and Maria Paola Costi

**NEW!** European Partnership: One Health Anti-Microbial Resistance

### HORIZON-HLTH-2024-DISEASE-09-01

https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportunities/topic-details/horizonhlth-2024-disease-09-01?status=31094501,31094502&frameworkProgramme=43108390&callIdentifier=HORIZON-HLTH-2024-DISEASE-09&order=DESC&pageNumber=1&pageSize=10&sortBy=startDate

Planned opening date 25 April 2024 Deadline date 25 September 2024 17:00:00 Brussels time

HORIZON-COFUND HORIZON Programme Cofund Actions

• Antimicrobials including antibiotics, antiparasitic, and antifungals, are subjected to resistance. In this context, Public Health Organizations called for a One Health approach because antimicrobials used to treat different infectious diseases in animals and plants may be the same than those used in humans.

### One Health. 2022 Jun; 14: 100368.

### Published online 2021 Dec 21. doi: 10.1016/j.onehlt.2021.100368

Antimicrobials including antibiotics, antiparasitic, and antifungals, are subjected to resistance. In this context, Public Health Organizations called for a One Health approach because antimicrobials used to treat different infectious diseases in animals and plants may be the same than those used in humans. Whereas mechanisms of resistance transmission from animals or environment to humans should be considered differently if related to prokaryotic or eukaryotic pathogens, their impact can be considered as a whole. In that respect, we discussed the use of anti-parasitic in animals including anticoccidials, anthelmintics, and insecticides-acaricides, and the use of azoles in the environment that may both favor the development of drug resistance in humans. In light of the current situation, there is an urgent need for a transdisciplinary approach through anti-parasitic and antifungal stewardship programs in humans, animals, and environment, especially in the era of COVID-19 pandemic that will probably aggravate antimicrobial resistance.

European Commission	, EU Fu	Inding & Ten	ders Porta	I			Sign in
••• · · · · · · · · · · · · · · · · · ·	Procurement 🔻	Projects & results ▼	News & events ▼	Work as an expert	Guidance & documents ▼		Search
ome > Funding > Calls for p	proposals > Euro	opean Partnership: One He	alth Anti-Microbial Re	sistance			
uropean Partne	•		licrobial Re	sistance			
Call for proposal							
ternal navigation	General in	formation					
General information	Programme Brownward Programma Budget overview						
Topic description	Horizon EL (HORIZON	ırope Framework Prograı I)	nme	Budget overview			
Destination	Call Partnershi	ps in Health (2024) (HOR	IZON-HLTH-2024-D	ISEASE-09)			
Conditions and docume	Type of ac	tion	Τ	pe of MGA		( Forthcoming )	
Partner search announ	HORIZON	HORIZON-COFUND HORIZON Programme Cofund Actions		HORIZON Action Grant Budget-Based [HORIZON- AG]			
Start submission	Deadline r	Deadline model single-stage		Planned opening date 25 April 2024		Deadline date 25 September 2024 17:00:00 Brussels time	
Topic Q&As	single-stag						
Get support							

I am sending a short list of possible applications that could be of interest for this network.

You can organize your collaboration including our network participants but also outside of it.

#### The below reported calls are expiring in a few days.

The Horizon Europe Global Health EDCTP3 Joint Undertaking has published its <u>work programme</u> <u>2024</u>. Calls will open on 18th January with deadline for the first stage on the 4th of April.

The call for proposals HORIZON-JU-GH-EDCTP3-2024-01-two-stage covers <u>six topics</u> for Research and Innovation Actions (RIA). Topics include HIV therapeutics, research on Malaria vaccines, Neglected Tropical Diseases, antimicrobial resistance, vector control, and digital health solutions:

- **HORIZON-JU-GH-EDCTP3-2024-01-02-two-stage**: Research on existing Malaria vaccines and development of new promising candidates

*Expected EU contribution per project*: EUR 15 million *Indicative budget for the topic*: EUR 30 million. *Type of Action*: RIA (Research and Innovation Action)

- HORIZON-JU-GH-EDCTP3-2024-01-03-two-stage: Accelerating development and integration of therapeutics against Neglected Tropical Diseases (NTDs) in sub-Saharan Africa *Expected EU contribution per project*: EUR 5 million *Indicative budget for the topic*: EUR 22 million. *Type of Action*: RIA (Research and Innovation Action)

- HORIZON-JU-GH-EDCTP3-2024-01-05-two-stage: New tools, technologies and approaches for vector control in sub-Saharan Africa *Expected EU contribution per project*: EUR 6.14 million *Indicative budget for the topic*: EUR 18.432 million. *Type of Action*: RIA (Research and Innovation Action) - **HORIZON-JU-GH-EDCTP3-2024-01-06-two-stage**: Innovative digital health solutions for sub-Saharan Africa *Expected EU contribution per project*: EUR 5 million *Indicative budget for the topic*: EUR 20 million.

*Type of Action*: RIA (Research and Innovation Action)

# 2. Interested in ITN? OHD contact: Theodora Calogeropoulou and Maria Laura Bolognesi

https://cordis.europa.eu/programme/id/H2020\_MSCA-ITN-2020

## 3. Weave projects

Collaborative projects- intra european projects - Weave participating countries:

Weave is a **bottom-up cross-European initiative** developed by European research funders – and embedded in Science Europe – to support excellent European collaborative research projects across national and regional borders. Based on the **Lead Agency Principle**, Weave aims to simplify the submission and selection procedure of collaborative project proposals: a European team of **researchers from two to three European countries or regions** that have signed the Weave initiative, submits their joint project proposal to only one research funder (Lead Agency) who is responsible for the entire administrative procedure and scientific evaluation. Each research funder involved is as such responsible for the payment of its own researchers (i.e. researchers eligible for funding from this research funder). Since Weave will enable **bilateral as well as trilateral scientific cooperation within Europe**, it will contribute to the **realisation of the European Research Area (ERA)**.

- Belgium (FWO): <u>https://www.fwo.be/en/fellowships-funding/international-collaboration/intra-</u> european-research-projects/weave/

- Belgium (FNRS): <u>https://www.frs-fnrs.be/en/financements/credits-et-projets/262-en/nos-financements/credits-et-projets/weave</u>

- Sweden (Formas): <u>https://formas.se/en/start-page/other/weave---simplified-funding-procedures-for-projects-across-european-borders.html</u>

- Germany (DFG): https://www.dfg.de/en/research-funding/funding-

opportunities/programmes/international-cooperation/joint-proposal-weave-process

- Luxembourg (FNR): https://www.fnr.lu/international-cooperation/weave/
- Switzerland (SNSF): <u>https://www.snf.ch/en/CxcoLbDNRaUwHIoH/funding/projects/weave</u>
- Austria

(FWF): <u>https://www.fwf.ac.at/fileadmin/Website/Dokumente/Foerdern/Portfolio/Laenderkooperationen/fwf</u> weave information\_for\_applicants.pdf

- Slovenia (ARRS): <u>http://www.aris-rs.si/en/medn/vodilna/index.asp</u>
- Poland (NCN): <u>https://ncn.gov.pl/en/wspolpraca-zagraniczna/wspolpraca-wielostronna/weave</u>
- Czech Republic (GACR): <u>https://gacr.cz/en/overview/weave-initiative/</u>
- Croatia (HRZZ): https://hrzz.hr/en/funding-programmes/international-cooperation/

### 4. Check bellow the 2024 open calls for proposals under Horizon Europe Cluster 1 'Health'

Under destination 3 "Tackling diseases and reducing disease burden" the calls address pandemic preparedness and response:

HORIZON-HLTH-2024-DISEASE-08-20 (**RIA**) Pandemic preparedness and response: Host-pathogen interactions of infectious diseases with epidemic potential

HORIZON-HLTH-2024-DISEASE-08-12 (**CSA**) Pandemic preparedness and response: Maintaining the European partnership for pandemic preparedness

Under destination 5 "Unlocking the full potential of new tools, technologies and digital solutions for a healthy society" the call focuses on bio-printing of living cells for regenerative medicine:

HORIZON-HLTH-2024-TOOL-11-02 (RIA) Bio-printing of living cells for regenerative medicine

## Under destination 6 "Maintaining an innovative, sustainable and globally competitive health industry" the calls focus on fostering innovation in the health industry:

<u>HORIZON-HLTH-2024-IND-06-08</u> (**RIA**) Developing EU methodological frameworks for clinical/performance evaluation and post-market clinical/performance follow-up of medical devices and in vitro diagnostic medical devices (IVDs)

<u>HORIZON-HLTH-2024-IND-06-09</u> (**CSA**) Gaining experience and confidence in New Approach Methodologies (NAM) for regulatory safety and efficacy testing – coordinated training and experience exchange for regulators

The deadline to apply to these calls is on **11 April 2024, 17:00 CEST**.

I hope you may successfully start grant applications, build consortia also including our participants. We will dedicate a meeting about this, upon requests, to help in case of interest. Do not hesitate to contact your Colleagues and discuss your next project.

To favor and trigger this grant application action within OHD, it will be very useful the filing of the survey sent you recently.

Please, complete the survey to support our activity to interconnect our network members!

#### Useful links

<u>https://ec.europa.eu/info/funding-</u> <u>tenders/opportunities/portal/screen/support/news?pageNumber=1&pageSize=5</u> <u>https://op.europa.eu/en/home</u> https://www.hrb.ie/news/news-story/article/eu-funding-updates-february-2024/

### **10. Surveys status – 2 SURVEYS closed. Monitoring of the open ones.**

Surveys Launched in YEAR 1



#### SURVEY 1 Status completed

This will circulate soon.

Survey on research perspectives for drug development targeting vector-borne diseases and environmental impact" by Clara Lima. You have received the entry SURVEY entitled " This data collection (or survey) was prepared by Clara and some Collaborators. We are expecting to achieve the 95% coverage of the network participants. This data collection represents the entry ID for all new OneHealthdrugs applicants. Clara has prepared a report and a paper is almost ready. SURVEY 2 Status completed Survey on compounds database (WG1) is turning to a compound collection (chemical compound structure database, only virtual collection). Regarding external available Database: Our website report the database selected by the network participants, under the following field WORKING AREA-> Database collections, open sources and vendors. The survey results is enclosed in this e-mail and is deposited in FairdomHub with the following DOI https://doi.org/10.15490/fairdomhub.1.document.4187.1. g SURVEY 3 about HITS and LEADS profile is turning to a compound collection (chemical compound structure database, only virtual collection) SURVEY 3 is conducted by WG2 and WG3 with the aim of collecting information from the network about the most important compounds existing among the network members that can respect the HITS or LEAD profile. The use of the structural-chemical information will be useful for further medicinal chemistry application in the field. This activity is in line with WG1 activity on compound database collection. The excel files containing the HITS and LEADS profile have been distributed among WG2 and WG3 for now, and will be corrected and updated. Finally, it will be distributed to the whole network for inclusion of all available compounds. 1st pa SURVEY 4 Available technologies within COST Action OneHealthDrugs This survey is developed to collect technologies used by the members of the COST Action CA21111 "One Health drugs against parasitic vector borned iseases in Europe and beyond" (OneHealthDrugs).

From Survey 1 a paper is under submission. From survey 2, a new paper is under writing.

This has not circulated yet. It deals with the selection of the technologies in use from the reported list.

## SURVEY 5 - YEAR 2

[Action Needed]: Please complete the First Exploitation Interest survey and join our brand new LinkedIn group Central to our mission is the enhancement of the OHD Compound Database (OHD-DB), a cornerstone of our Memorandum of Understanding, a catalyst for fostering meaningful collaborations both within and extending beyond OHD CA21111. Your expertise and input are key to achieving our strategic objectives: Broaden our Compound Reach: Your active participation in the coordinated screening of compounds is critical. It's not just about expanding our database, but about spearheading innovation in the crucial area of anti-parasitic drug discovery. Maximise One Health Impact: We rely on your unique perspectives to deepen our understanding of compound design and screening. Your insights have the power to drive significant advancements in the impact of One Health Drugs.

Another integral reason for your participation in the survey is to consolidate our human capital. This is about more than just gathering data; it's about uniting our diverse expertise and experiences to form a robust, cohesive consortium. Your

input helps us map the vast array of skills and knowledge within our community, enabling us to harness our collective strength more effectively. Moreover, this survey serves as your platform to express interest in EU funding programmes. This is more than just a survey; it's our gateway to initiating successful grant applications and forming impactful consortia, potentially

involving our members. Understanding the importance of this, we are ready to organise a dedicated meeting to support your interests in these areas. Engage with your colleagues, discuss potential projects, and let's turn these conversations into concrete actions. Completing this survey is not only beneficial—it's essential for catalysing grant applications and fostering stronger connections within our OHD network. Yourresponse is a crucial step

## 11.SciCom activity (Theo you describe this section)

- > Media reminders
- Linkedin reminder
- > OHD report to fill

Please remember to fill the OHD report, please find here the link:

https://docs.google.com/spreadsheets/d/1GcCwuYN0IqP8R7gEiRngDFiWzLoGqxNuwXMm6rnVLE/edit#gid=0